Cargando…
Mebeverine for Pediatric Functional Abdominal Pain: A Randomized, Placebo-Controlled Trial
We evaluated the effectiveness of an antispasmodic, mebeverine, in the treatment of childhood functional abdominal pain (FAP). Children with FAP (n = 115, aged 6–18 years) received mebeverine (135 mg, twice daily) or placebo for 4 weeks. Response was defined as ≥2 point reduction in the 6-point pain...
Autores principales: | Pourmoghaddas, Zahra, Saneian, Hossein, Roohafza, Hamidreza, Gholamrezaei, Ali |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4095832/ https://www.ncbi.nlm.nih.gov/pubmed/25089264 http://dx.doi.org/10.1155/2014/191026 |
Ejemplares similares
-
Synbiotic containing
Bacillus coagulans
and fructo-oligosaccharides for functional abdominal pain in children
por: Saneian, Hossein, et al.
Publicado: (2015) -
Psychological Status and Quality of Life in relation to the Metabolic Syndrome: Isfahan Cohort Study
por: Roohafza, Hamidreza, et al.
Publicado: (2012) -
A Potential Role of Ethosuximide and Pentoxifylline in Relieving Abdominal Pain in Irritable Bowel Syndrome Patients Treated with Mebeverine: A Randomized, Double-Blind, Placebo-Controlled Trial
por: El-Haggar, Sahar M, et al.
Publicado: (2022) -
A Possible Role for Pioglitazone in the Management of Depressive Symptoms in Metabolic Syndrome Patients (EPICAMP Study): A Double Blind, Randomized Clinical Trial
por: Roohafza, Hamidreza, et al.
Publicado: (2014) -
A Potential Role of Ethosuximide and Pentoxifylline in Relieving Abdominal Pain in Irritable Bowel Syndrome Patients Treated with Mebeverine: A Randomized, Double-Blind, Placebo-Controlled Trial [Retraction]
Publicado: (2022)